Key Points Revenue (GAAP) climbed 73% year over year in the second quarter of 2025 but missed consensus estimates by 1.2%. Net income (GAAP) and Adjusted EBITDA more than doubled, while gross margin ...

Lilly's valuation seems reasonable given its growth prospects. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY ...

Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming ...

Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required ...

In June, Novo Nordisk ( NVO) ended a brief partnership that allowed Hims & Hers members to access its weight loss drug, Wegovy. The termination was due to concerns that the company was violating ...

Shares of Hims & Hers Health fell 10% in afterhours trading on Monday after the telehealth company reported second-quarter ...

Now, it’s worth noting Stock Advisor’s total average return is 1,019% — a market-crushing outperformance compared to 178 % ...

Novo Nordisk A/S (NYSE: NVO) is one of the top cheap pharmaceutical stocks to buy now. On August 1, Bernstein analyst Florent ...

Street expects $552 million in revenue and $0.15 EPS as subscriber growth and GLP-1 demand fuel optimism, just as legal ...